Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass
Bart Keymeulen(Vrije Universiteit Brussel), Daniël Pipeleers(Vrije Universiteit Brussel), Christophe De Block(University of Antwerp), Laurent Crenier(Université Libre de Bruxelles), Sophie Candon, Chantal Mathieu(KU Leuven), Lucienne Chatenoud(Hôpital Necker-Enfants Malades), Robert Hilbrands, Melanie Walter(The University of Sydney), Frans Gorus(Vrije Universiteit Brussel), Herman Waldmann(University of Cambridge), A G Ziegler(München Klinik Schwabing), Ursule Van de Velde(Center for Beta Cell Therapy in Diabetes), L. Kaufman, Evy Vandemeulebroucke(Center for Beta Cell Therapy in Diabetes)
Cited by 313
Related Papers
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2022|1.9k
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetologia|2022|986
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
|Blood|2000|502
ELIMINATION OF GRAFT-VERSUS-HOST DISEASE BY IN-VITRO DEPLETION OF ALLOREACTIVE LYMPHOCYTES WITH A MONOCLONAL RAT ANTI-HUMAN LYMPHOCYTE ANTIBODY (CAMPATH-1)
|The Lancet|1984|424
High Doses of Vitamin D to Reduce Exacerbations in Chronic Obstructive Pulmonary Disease
|Annals of Internal Medicine|2012|362